AstraZeneca PLC

AstraZeneca's Datroway wins EU approval in metastatic breast cancer

Datroway's EU approval adds a second breast cancer indication, supported by improved survival and progression-free survival versus chemotherapy.

AstraZeneca H1 results: growth holds up despite pipeline setbacks

AstraZeneca delivered higher H1 revenue and core earnings, supported by oncology, while reconfirming its 2026 guidance and raising the dividend.

AstraZeneca Q1 2026 Results: Strong Revenue Growth and Positive Pipeline Readouts

AstraZeneca Bolsters Weight Management Portfolio with $1.2B CSPC Deal

AstraZeneca's $1.2bn CSPC deal secures once-monthly obesity injections and AI-driven peptide tech, expanding its weight management pipeline.

AstraZeneca Strikes Historic Deal with US Government to Slash Drug Prices

AstraZeneca slashes US drug prices by 80% in historic government deal, boosting manufacturing with a $50B investment for future growth.

AstraZeneca Reports Strong H1 Growth and $50 Billion US Investment Pledge

AstraZeneca reports stellar H1 growth with 11% revenue surge and pledges $50B US investment for Virginia manufacturing hub, powering future metabolic pipeline expansion. (148 characters)